MorphoSys seeks to proceed to Phase IIa with its lead HuCAL product in RA
This article was originally published in Scrip
MorphoSys is seeking authorisation to begin a Phase Ib/IIa study in Europe of its lead drug MOR103, a fully human HuCAL-derived monoclonal antibody directed against granulocyte macrophage-colony stimulating factor (GM-CSF), in patients with active rheumatoid arthritis.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.